Work

Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trial

Year: 2025

Type: article

Source: Contemporary Clinical Trials

DOI: 10.1016/j.cct.2025.107887

Authors: Mark J. Giganti, Kara W. Chew, Carlee Moser, Joseph J. Eron, Mauricio Pinilla, Jonathan Z. Li, Justin Ritz, Arzhang Cyrus Javan, David Alain Wohl, Eric S. Daar, Judith S. Currier, Davey M. Smith, Michael D. Hughes

Institutions: Harvard University, University of California, Los Angeles, University of North Carolina at Chapel Hill, Brigham and Women's Hospital, National Institutes of Health, The Lundquist Institute, Harbor–UCLA Medical Center, University of California San Diego

Language: English

Topic: Statistical Methods in Clinical Trials

Subfield: Statistics and Probability

Field: Mathematics

Domain: Physical Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Gilead Sciences, University of Washington, ViiV Healthcare, ACT Government, National Institutes of Health, National Institute of Allergy and Infectious Diseases

Awards: G1050281965, G1636177350, G2911661195, G4553935269, G5316515788, G5514976981, G650174051, G681742546, G857487509, G9000047228, G9000182931, SDMC - IMPAACT Leadership Group, AIDS Clinical Trial Group Laboratory Center, Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplication

OpenAlex ID: W4408866876

FWCI: 0.832

Cites: 18

Cited by: 1

Related to: 10